ClinicalTrials.gg
Not yet recruitingNCT07282769Updated Jun 10, 2026

Semaglutide (Wegovy) Treatment for Trichotillomania

A Phase 2 interventional study of Semaglutide in Trichotillomania (Hair-Pulling Disorder), Trichotillomania and Hair Pulling Disorder, sponsored by University of Chicago. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-10.

Sponsored by University of Chicago · Phase 2, Interventional, and Treatment

How we know · 4 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Trichotillomania by University of Chicago — 2 open to participants now, 3 under way, 1 of them phase 3. Trichotillomania · University of Chicago.

Planned enrollment
10th of 11
10 · median 38
Started
2026
with 1 other
Phase 2
9 of 11
2 open now
Registered
11th of 11
by date

Among the 11 studies in Trichotillomania by University of Chicago, this one is the 10th largest by planned enrollment, is one of 2 that started in 2026, is one of 9 in phase 2, and was the 11th registered.

Trichotillomania

48 studies on the registry are indexed under Trichotillomania; 8 are open to participants now.

Browse Trichotillomania studies →

Open to participants now

2 of the 11 studies in Trichotillomania by University of Chicago are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 6 Trichotillomania studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Trichotillomania by University of Chicago, or all of them as a file.
02

Study summary

This research study is testing the effectiveness and safety of semaglutide (Wegovy) in people with trichotillomania, also known as hair-pulling disorder.

Read the detailed description

The goal of the proposed study is to evaluate the efficacy and safety of semaglutide in individuals with trichotillomania. The hypothesis to be tested is that semaglutide will reduce urges to pull hair and pulling behavior and will be well tolerated in participants with trichotillomania. The proposed study will provide needed pilot data on the treatment of a disabling disorder that currently lacks available options for pharmacological treatment.

The investigators will conduct an open-label pharmacotherapy trial in 10 individuals with trichotillomania. Participants with trichotillomania will be started and continued on medication during an 8-week treatment phase. The study will be the first to use a once weekly Glucagon-like peptide 1 (GLP-1) receptor agonist pharmacological intervention to target urges in trichotillomania and thereby has the potential to set a new standard of care for a range of compulsive behaviors.

03

Conditions studied

  • Trichotillomania (Hair-Pulling Disorder)
  • Trichotillomania
  • Hair Pulling Disorder
  • Hair Pulling
  • Hair-Pulling Disorder

Browse trials for

Keywords

  • trichotillomania
  • hair pulling
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women age 18-75;
  2. Diagnosis of current trichotillomania based on criteria and confirmed using the clinician-administered MIDI (13);
  3. Hair pulling daily with urges to pull as the trigger in >50% of the episodes of pulling;
  4. Women of childbearing age are required to have a negative result on a beta-human chorionic gonadotropin pregnancy test;
  5. Women of utilizing a medically accepted form of defined as double barrier, oral contraceptive, injectable contraceptive, implantable contraceptive devices, and abstinence

Exclusion criteria

Exclusion Criteria:

  1. Infrequent pulling (i.e. less than daily) or automatic pulling (i.e. no urges to pull);
  2. Unstable medical illness or abnormalities on laboratory tests, , or physical examination at screen as determined by the investigator;
  3. History of seizures;
  4. Myocardial infarction within 6 months;
  5. Current pregnancy or lactation, or inadequate in women of ;
  6. A need for medication other than semaglutide with possible psychotropic effects or unfavorable interactions as determined by the investigator;
  7. Clinically significant suicidality (defined by the Columbia Suicide-Severity Rating Scale);
  8. Lifetime history of bipolar disorder type I or II, schizophrenia, or any psychotic disorder;
  9. Current skin picking disorder;
  10. Initiation of psychotherapy or behavior therapy within 3 months prior to study baseline;
  11. Initiation of psychotropic medications within 3 months prior to study baseline (stable doses will be allowed);
  12. Previous treatment with semaglutide;
  13. Use of any weight loss medications;
  14. (BMI, calculated as weight in kilograms divided by height in meters squared) less than 23;
  15. Past-year substance use disorder other than tobacco use disorder or mild cannabis use disorder;
  16. Recent (30-day) use of illicit drugs except cannabis;
  17. History of diabetes, and current medical or neurological illness precluding participation based on physician judgment;
  18. Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia 2A or 2B;
  19. History of pancreatitis.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Semaglutide (Wegovy)

    Participants will receive semaglutide (Wegovy) weekly for 8 weeks.

    Drug: Semaglutide

Interventions

  • All participants in the study will receive semaglutide (Wegovy).

    Also known as: Wegovy

06

What researchers measure

Primary outcomes

  1. NIMH Trichotillomania Severity Scale

    Clinician-rated scale assessing trichotillomania symptom severity over the past week that will be administered at all visits. Total scores range from 0-20. Higher scores indicate greater severity.

    Time frame: From screening to 1 week after last dose of study drug

Secondary outcomes

  1. Clinical Global Impression-Improvement and Severity Scales

    Clinician-administered scale consisting of two reliable and valid 7-item Likert scales used to assess severity and change in clinical symptoms. The CGI-S will be used at screening and the CGI-I will be used at every visit after screening. the CGI-S ranges from 1 = "not ill at all" to 7 = "among the most extremely ill." The CGI-I scale ranges from 1 = "very much improved" to 7 = "very much worse."

    Time frame: From screening to 1 week after last dose of study drug

  2. Massachusetts General Hospital Hair Pulling Scale

    A 7-item self-report measure assessing trichotillomania severity over the past week. Total scores range from 0-28. Greater scores indicate worse symptoms.

    Time frame: From screening to 1 week after last dose of study drug

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Feb 2027, 8 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2025
First posted
Dec 15, 2025
StartEst.
Jun 2026
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Jun 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07282769
Responsible party
Sponsor
First posted
Dec 15, 2025
Start date
Jun 2026 (estimated)
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Jun 10, 2026

Study contacts

Sofia Vicenzino, BA
Contact
sofia.vicenzino@bsd.uchicago.edu
773-702-9066
Estelle Spira, BS
Contact
estelle.spira@bsd.uchicago.edu
773-834-3778
Jon E Grant, MD, JD, MPH
principal investigator · University of Chicago

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion